Kung-Chi Chang - Publications

Affiliations: 
2013-2021 Stony Brook University (USA) 

7 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Chang KC, Spector DL. : a long non-coding RNA involved in breast cancer progression. Molecular & Cellular Oncology. 8: 1882286. PMID 33860086 DOI: 10.1080/23723556.2021.1882286  0.758
2020 Chang KC, Diermeier SD, Yu AT, Brine LD, Russo S, Bhatia S, Alsudani H, Kostroff K, Bhuiya T, Brogi E, Pappin DJ, Bennett CF, Rigo F, Spector DL. MaTAR25 lncRNA regulates the Tensin1 gene to impact breast cancer progression. Nature Communications. 11: 6438. PMID 33353933 DOI: 10.1038/s41467-020-20207-y  0.636
2017 Liu CY, Tseng LM, Su JC, Chang KC, Chu PY, Tai WT, Shiau CW, Chen KF. Erratum to: Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. Breast Cancer Research : Bcr. 19: 5. PMID 28077164 DOI: 10.1186/s13058-017-0800-2  0.392
2016 Diermeier SD, Chang KC, Freier SM, Song J, El Demerdash O, Krasnitz A, Rigo F, Bennett CF, Spector DL. Mammary Tumor-Associated RNAs Impact Tumor Cell Proliferation, Invasion, and Migration. Cell Reports. 17: 261-74. PMID 27681436 DOI: 10.1016/J.Celrep.2016.08.081  0.733
2015 Arun G, Diermeier S, Akerman M, Chang KC, Wilkinson JE, Hearn S, Kim Y, MacLeod AR, Krainer AR, Norton L, Brogi E, Egeblad M, Spector DL. Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss. Genes & Development. PMID 26701265 DOI: 10.1101/Gad.270959.115  0.53
2013 Liu CY, Tseng LM, Su JC, Chang KC, Chu PY, Tai WT, Shiau CW, Chen KF. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. Breast Cancer Research : Bcr. 15: R63. PMID 23938089 DOI: 10.1186/bcr3457  0.447
2012 Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW, Chen KF. CIP2A is a target of bortezomib in human triple negative breast cancer cells Breast Cancer Research. 14. PMID 22537901 DOI: 10.1186/bcr3175  0.571
Show low-probability matches.